-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 5-10% of COVID-19 patients develop severe acute respiratory distress syndrome (ARDS) or multiple visceral failure
.
Of those who develop the severe form, 71-75% require mechanical ventilation and approximately 50% die
About 5-10% of COVID-19 patients develop severe acute respiratory distress syndrome (ARDS) or multiple visceral failure
This study is a single-center retrospective study of COVID-19-infected populations
.
Muscle mass (skeletal muscle index (SMI)) estimates for sarcopenia, muscle mass, and muscle density measures for body adiposity were measured based on CT at T4 and L3 levels measured at admission
statistics
A total of 162 patients (92 males and 70 females, mean age 64.
6 years, mean BMI 27.
2 2 2 2
Figure: Diagram of chest muscles (red)
This study showed that sarcopenia of the chest and abdomen was independently associated with an increased risk of intensive care unit hospitalization, suggesting the need to assess sarcopenia on admission during COVID-19 infection
.
.
Original source:
J.
Thoracic sarcopenia as a predictive factor of SARS-COV2 evolution.
Leave a comment here